MedTrace Logo

Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies

NCT01021085 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2011-09-05

No results posted yet for this study

Summary

Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART). The samples will be used to develop a prenatal sex test using circulating cell free fetal DNA (ccffDNA) in maternal plasma or urine.

Conditions

  • Fetal Sex Determination

Sponsors & Collaborators

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Allan Bombard, MD MBA · Sequenom, Inc.

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01021085 on ClinicalTrials.gov